11:09 AM
 | 
Nov 16, 2016
 |  BC Extra  |  Clinical News

Mixed Phase III results for Gilead's momelotinib in myelofibrosis

Gilead Sciences Inc. (NASDAQ:GILD) announced mixed results from two Phase III studies of momelotinib (formerly CYT387) to treat myelofibrosis. The candidate showed non-inferiority to Jakafi ruxolitinib on the SIMPLIFY-1 trial's primary endpoint, but failed to show superiority to...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >